Event Details

Name: MaxCyte Third Quarter Earnings Conference Call
Start: 2026-11-10T21:30:00

MaxCyte Third Quarter Earnings Conference Call

Add to Outlook

Add to Google Calendar

ATx

From small to medium static Electroporation.

STx

Transfect up to 20 billion cells with scalable static or Flow Electroporation®.

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant Flow Electroporation®.

VLx

For gram scale protein production.

Processing Assemblies

Achieve the desired scale and throughput with a range of consumable devices.

Reagents & Supporting Products

Complement your workflow with our flexible electroporation buffer formats and accessories.

Discover scalable engineering to enable safe and potent cell therapies.

Navigate the complexities of genome engineering with highly efficient delivery.

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Produce assay-ready cells faster with scalable electroporation.

Transfect adherent or suspension cells to produce a variety of viral vectors.

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles.

Partnering with developers to accelerate development and scale cell therapy programs toward clinical success.

Accelerating breakthrough discoveries with high-efficiency, reproducible electroporation across cell types.

Enabling efficient, reproducible transfection in virtually any cell type for high-yield transient expression and rapid cell line development.